New tumor markers determine therapy intensity

March 18, 2009

Genetic aberrations in childhood brain tumors provide precise information on the course of the disease; Heidelberg researchers publish in the Journal of Clinical Oncology

Characteristic changes in the DNA of medulloblastoma, the most frequent malignant brain tumor in childhood, indicate precisely how aggressively the tumor will continue to spread and what the chances of disease relapse are. Researchers at the Center for Pediatric and Adolescent Medicine at the Heidelberg University Hospital and the German Cancer Research Center have discovered this correlation. With this new set of tumor markers, the intensity of treatment can be adjusted individually and the potentially damaging effects reduced. The results have now been published online in the prestigious Journal of Clinical Oncology.

Medulloblastoma is the most frequent childhood brain tumor

The most common malignant brain tumor in childhood is the medulloblastoma - every year, more than 100 children in Germany develop this tumor of the cerebellum and some 30-40 children die from it. The first symptoms generally appear at primary school age, but the tumor, which can already arise during embryonal development, can also occur in babies and toddlers. Aggressive radiation and chemotherapy regimens after surgery can permanently damage the brain of the growing child, for example, leading to coordination disorders and limited growth.

"Using the characteristic changes in the genetic makeup of medulloblastoma, we can predict more accurately than with conventional methods how a patient will respond to therapy and how great the risk is that the tumor will return after surgery and subsequent radiation and chemotherapy," explained Dr. Stefan Pfister, who works with his team in the department of pediatric oncology at the Center for Pediatric and Adolescent Medicine (Medical Director: Professor Dr. Dr. Andreas Kulozik) and in the department of molecular genetics at the German Cancer Research Center (Director: Professor Dr. Peter Lichter). Thus far, oncologists could estimate this risk only on the basis of histology findings, age at diagnosis, residual tumor after surgery, and existence of metastases at diagnosis.

Patients with a poor prognosis can be treated more intensively

Stefan Pfister and his research group "Molecular Genetics of Pediatric Brain Tumors" first described the new tumor markers in the medulloblastoma in 2007. For the current study, he examined tumor samples from 340 patients and compared the documented course of disease with genetic aberrations in the tumor DNA. Aberrations were seen at the chromosome level, the units in which the entire genetic information is distributed and contained. Each chromosome contains large amounts of genetic information; the entire genetic material of humans is distributed in 23 such portions, each of which is usually present in two copies (2 x 23 chromosomes). Stefan Pfister discovered that if entire segments of chromosomes number 6 and 17 are present in three copies (instead of the usual 2 copies) in the genetic material of the brain tumors, the patient's prognosis is poor. If however, one copy of chromosome 6 is missing in the tumor, the patients in the collective observed always survived. The combination of these and other characteristics led to a classification of the patients in a total of five groups requiring varying levels of intensity in treatment.

"With these markers, we can reliably identify patients with a poor prognosis and treat them more intensely from the start," said Dr. Stefan Pfister. "At the same time, we can reduce the treatment intensity for patients who will presumably respond especially well to radiation and chemotherapy. We can thus reduce consequential damage and the risk of secondary malignancies."

Another advantage of the new markers - the test is very robust and can be carried out within 48 hours in any neuropathology laboratory on tissue samples conventionally preserved in paraffin.

BMBF promotes the search for other tumor markers

The prospective validation of these markers in an independent patient cohort and the search for the simplest and most reliable methods of analysis is now the goal of a project promoted by the Federal Ministry for Education and Research (BMBF) entitled "Molecular Diagnostics," in which the university hospitals of Bonn, Mainz, Düsseldorf, Würzburg, and Heidelberg as well as the German Cancer Research Center in Heidelberg are participating under the coordination of Dr. Stefan Pfister.

University Hospital Heidelberg

---

---

	Tumors of the Central Nervous System, Volume 8: Astrocytoma, Medulloblastoma, Retinoblastoma, Chordoma, Craniopharyngioma, Oligodendroglioma, and Ependymoma by M.A. Hayat (Editor) With tens of thousands of new CNS tumor cases each year in the US alone, this series of publications is a valuable aid to the diagnosis and treatment of these problematic neoplasms. Now, the eighth in the set returns to the topic of brain tumors, dealing with seven distinct types: astrocytoma, medulloblastoma, retinoblastoma, chordoma, craniopharyngioma, oligodendroglioma, and ependymoma. After updating the classification of medulloblastoma the volume provides an overview of ependymoma as well as describing the delineation of prognosis based on the genetic aberrations of the latter patients. The material offers key insights into the molecular pathways involved in tumor biology, such as the role of E-cadherin gene instability, carbonic anhydrase II, urokinase plasminogen activator, and Wnt...
	The Official Parent's Sourcebook on Childhood Medulloblastoma: A Revised and Updated Directory for the Internet Age by Icon Health Publications (Author) This sourcebook has been created for parents who have decided to make education and Internet-based research an integral part of the treatment process. Although it gives information useful to doctors, caregivers and other health professionals, it also tells parents where and how to look for information covering virtually all topics related to childhood medulloblastoma, from the essentials to the most advanced areas of research. The title of this book includes the word official. This reflects the fact that the sourcebook draws from public, academic, government, and peer-reviewed research. Selected readings from various agencies are reproduced to give you some of the latest official information available to date on childhood medulloblastoma. Following an introductory chapter, the sourcebook...
	21st Century Pediatric Cancer Sourcebook: Brain and Spinal Cord Tumors - Neuroectodermal, Medulloblastoma, Glioma, Astrocytoma, Craniopharyngioma, Craniopharyngioma, CNS Tumors, Others by Progressive Management Authoritative information and practical advice from the nation's cancer experts about childhood brain and spinal cord tumors, including neuroectodermal tumors, medulloblastomas, gliomas, astrocytomas, craniopharyngiomas, craniopharyngiomas, CNS tumors, and others. Starting with the basics, and advancing to detailed patient-oriented and physician-quality information, this comprehensive compilation gives empowered patients, families, caregivers, nurses, and physicians the information they need to understand the diagnosis and treatment of this disease. In addition to disease-specific information, this ebook includes a glossary and information on the late effects of treatment for childhood cancer and pediatric supportive care. There are many types of childhood brain and spinal cord tumors....
	Gale Encyclopedia of Cancer: Medulloblastoma by D.O., M.P.H. Edward R. Rosick (Author) The article is excerpted from Gale Encyclopedia of Cancer The resource students and researchers will turn to for reliable, up-to-date and clearly written information, the Gale Encyclopedia of Cancer is a comprehensive survey of 120 cancers, cancer drugs, traditional and alternative treatments and diagnostic procedures. The Encyclopedia includes entries covering cancers, cancer drugs, treatments, side effects and diagnostic procedures. Entries typically include the following elements: Causes and Symptoms Definition Description Diagnosis Prevention Resources Risks Special Concerns And more An appendix provides complete contact information for cancer centers, national support groups, government agencies and research groups. Features include anatomical...
	Dysarthria following cerebellar mutism secondary to resection of a fourth ventricle medulloblastoma: a case study.(risk factors): An article from: Journal of Medical Speech - Language Pathology by Yu-Tsai Wang (Author), Ray D. Kent (Author), Joseph R. Duffy (Author), Jack E. Thomas (Author), Geoffrey V. Fredericks (Author) This digital document is an article from Journal of Medical Speech - Language Pathology, published by Thomson Gale on June 1, 2006. The length of the article is 7188 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Dysarthria following cerebellar mutism secondary to resection of a fourth ventricle medulloblastoma: a case study.(risk factors) Author: Yu-Tsai Wang Publication: Journal of Medical Speech - Language Pathology (Magazine/Journal) Date: June 1, 2006 Publisher: Thomson Gale Volume: 14 Issue: 2 Page: 109(14) Distributed by Thomson...
	Medulloblastoma: An entry from Thomson Gale's Gale Encyclopedia of Cancer, 2nd ed. by Edward, D.O., M.P.H. Rosick (Author) Students, researchers, and patients can find reliable, up-to-date and clearly written information in “The Gale Encyclopedia of Cancer,” a comprehensive survey of 120 cancers, cancer drugs, traditional and alternative treatments and diagnostic procedures.
	Medulloblastoma: Webster's Timeline History, 1949 - 2007 by Icon Group International (Author) Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Medulloblastoma," including when used in literature (e.g. all authors that might have Medulloblastoma in their name). As such, this book represents the largest compilation of timeline events associated with Medulloblastoma when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop culture, the arts,...
	21st Century Pediatric Cancer Sourcebook: Childhood Central Nervous System Embryonal Tumors - Medulloblastoma, Pineoblastoma, Pineal Parenchymal Tumors, PNET, Medulloepithelioma, Ependymoblastoma by Progressive Management Authoritative information and practical advice from the nation's cancer experts about childhood central nervous system embryonal tumors, which includes medulloblastomas, pineoblastomas, pineal parenchymal tumors, PNET, medulloepitheliomas, and ependymoblastomas. Starting with the basics, and advancing to detailed patient-oriented and physician-quality information, this comprehensive compilation gives empowered patients, families, caregivers, nurses, and physicians the information they need to understand the diagnosis and treatment of these diseases. Conveniently organized contents include: Diagnostic Evaluation * Predictors of Outcome * Cellular Classification * Staging * Treatment Option Overview - Risk Stratification for Medulloblastoma * Surgery * Radiation Therapy * Surveillance...
	Medulloblastoma - Pipeline Review, Q1 2011 by Global Markets Direct (Author) Medulloblastoma - Pipeline Review, Q1 2011 Summary Global Markets Direct’s, 'Medulloblastoma - Pipeline Review, Q1 2011', provides an overview of the Medulloblastoma therapeutic pipeline. This report provides information on the therapeutic development for Medulloblastoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Medulloblastoma. 'Medulloblastoma - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by...
	Clinical case study: a 4-year-old boy with posterior fossa syndrome after resection of a medulloblastoma.(Case study): An article from: Journal of Neuroscience Nursing by Diane Schretzman Mortimer (Author) This digital document is an article from Journal of Neuroscience Nursing, published by American Association of Neuroscience Nurses on August 1, 2011. The length of the article is 3170 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser. Citation Details Title: Clinical case study: a 4-year-old boy with posterior fossa syndrome after resection of a medulloblastoma.(Case study) Author: Diane Schretzman Mortimer Publication: Journal of Neuroscience Nursing (Magazine/Journal) Date: August 1, 2011 Publisher: American Association of Neuroscience Nurses Volume: 43 Issue: 4 Page: 225(5) Article Type: Case...